Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

Mediators of Inflammation

Volumn 2017, Issue , 2017, Pages

  Cantini, Fabrizio ^a   Nannini, Carlotta ^a   Niccoli, Laura ^a   Petrone, Linda ^b   Ippolito, Giuseppe ^b   Goletti, Delia ^b  

^a Hospital of Prato   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BIOLOGICAL PRODUCT; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INCIDENCE; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POSTMARKETING SURVEILLANCE; POSTPRIMARY TUBERCULOSIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ANIMAL; METABOLISM; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; TUBERCULOSIS;

ANIMALS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85021649960     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2017/8909834     Document Type: Review

References (193)

1. F. Cantini, L. Niccoli, and D. Goletti, "Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance," The Journal of Rheumatology. Supplement, vol. 91, pp. 47-55, 2014.
2. A. Souto, J. R. Maneiro, E. Salgado, L. Carmona, and J. J. Gomez-Reino, "Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies," Rheumatology (Oxford), vol. 53, no. 10, pp. 1872-1885, 2014.
3. F. Cantini, C. Nannini, L. Niccoli et al., "Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice," Autoimmunity Reviews, vol. 14, no. 6, pp. 503-509, 2015.
4. S. Minozzi, S. Bonovas, T. Lytras et al., "Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis," Expert Opinion on Drug Safety, vol. 15, no. Supplement 1, pp. 11-34, 2016.
5. F. Cantini, L. Niccoli, and D. Goletti, "Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries," The Journal of Rheumatology. Supplement, vol. 91, pp. 56-64, 2014.
6. WHO, "Global Tuberculosis report 2015," http://www.who. int/tb/publications/global-report/en/.
7. D. Falzon, H. J. Schünemann, E. Harausz et al., "WHO treatment guidelines for drug-resistant tuberculosis, 2016 update," European Respiratory Journal, vol. 49, no. 3, article 1602308, 2017.
8. D. Goletti, E. Petruccioli, S. A. Joosten, and T. H. Ottenhoff, "Tuberculosis biomarkers: from diagnosis to protection," Infectious Disease Reports, vol. 8, no. 2, p. 6568, 2016.
9. M. Dara, I. Solovic, G. Sotgiu et al., "Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices," The European Respiratory Journal, vol. 48, no. 3, pp. 808-817, 2016.
10. K. Lönnroth, G. B. Migliori, I. Abubakar et al., "Towards tuberculosis elimination: an action framework for lowincidence countries," The European Respiratory Journal, vol. 45, no. 4, pp. 928-952, 2015.
11. M. Raviglione and G. Sulis, "Tuberculosis 2015: burden, challenges and strategy for control and elimination," Infectious Disease Reports, vol. 8, no. 2, p. 6570, 2016.
12. E. Petruccioli, T. J. Scriba, L. Petrone et al., "Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis," The European Respiratory Journal, vol. 48, no. 6, pp. 1751-1763, 2016.
13. U. Mack, G. B. Migliori, M. Sester et al., "LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement," The European Respiratory Journal, vol. 33, no. 5, pp. 956-973, 2009.
14. S. Gagneux, K. DeRiemer, T. Van et al., "Variable hostpathogen compatibility in Mycobacterium tuberculosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2869-2873, 2006.
15. D. Brites and S. Gagneux, "Co-evolution of Mycobacterium tuberculosis and Homo sapiens," Immunological Reviews, vol. 264, no. 1, pp. 6-24, 2015.
16. R. M. Houben and P. J. Dodd, "The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling," PLoS Medicine, vol. 13, no. 10, article e1002152, 2016.
17. C. E. Barry 3rd, H. I. Boshoff, V. Dartois et al., "The spectrum of latent tuberculosis: rethinking the biology and intervention strategies," Nature Reviews. Microbiology, vol. 7, no. 12, pp. 845-855, 2009.
18. H. Esmail, C. E. Barry 3rd, D. B. Young, and R. J. Wilkinson, "The ongoing challenge of latent tuberculosis," Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 369, no. 1645, p. 20130437, 2014.
19. G. Delogu and D. Goletti, "The spectrum of tuberculosis infection: new perspectives in the era of biologics," The Journal of Rheumatology. Supplement, vol. 91, pp. 11-16, 2014.
20. A. A. Chackerian, J. M. Alt, T. V. Perera, C. C. Dascher, and S. M. Behar, "Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity," Infection and Immunity, vol. 70, no. 8, pp. 4501-4509, 2002.
21. A. J. Wolf, B. Linas, G. J. Trevejo-Nuñez et al., "Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo," Journal of Immunology, vol. 179, no. 4, pp. 2509-2519, 2007.
22. W. L. Chan, A. Rodgers, R. D. Hancock et al., "Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response," The Journal of Experimental Medicine, vol. 176, no. 4, pp. 1203-1207, 1992.
23. H. S. Choi, P. R. Rai, H. W. Chu, C. Cool, and E. D. Chan, "Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis," American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 2, pp. 178-186, 2002.
24. M. G. Gutierrez, D. B. Munafó, W. Berón, and M. I. Colombo, "Rab7 is required for the normal progression of the autophagic pathway in mammalian cells," Journal of Cell Science, vol. 117, no. Part 13, pp. 2687-2697, 2004.
25. D. Goletti, E. Petruccioli, A. Romagnoli, M. Piacentini, and G. M. Fimia, "Autophagy in Mycobacterium tuberculosis infection: a passepartout to flush the intruder out?" Cytokine & Growth Factor Reviews, vol. 24, no. 4, pp. 335-343, 2013.
26. E. Petruccioli, A. Romagnoli, M. Corazzari et al., "Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages," The Journal of Infectious Diseases, vol. 205, no. 9, pp. 1425-1435, 2012.
27. J. L. Casanova and L. Abel, "Genetic dissection of immunity to mycobacteria: the human model," Annual Review of Immunology, vol. 20, no. 1, pp. 581-620, 2002.
28. S. A. Khader, G. K. Bell, J. E. Pearl et al., "IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge," Nature Immunology, vol. 8, no. 4, pp. 369-377, 2007.
29. R. Gopal, L. Monin, S. Slight et al., "Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection," PLoS Pathogens, vol. 10, no. 5, article e10e04099, 2014.
30. A. Cruz, A. G. Fraga, J. J. Fountain et al., "Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis," The Journal of Experimental Medicine, vol. 207, no. 8, pp. 1609-1616, 2010.
31. T. M. Wozniak, B. M. Saunders, A. A. Ryan, and W. J. Britton, "Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon," Infection and Immunity, vol. 78, no. 10, pp. 4187-4194, 2010.
32. B. Nandi and S. M. Behar, "Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection," The Journal of Experimental Medicine, vol. 208, no. 11, pp. 2251-2262, 2011.
33. C. Nunes-Alves, M. G. Booty, S. M. Carpenter, P. Jayaraman, A. C. Rothchild, and S. M. Behar, "In search of a new paradigm for protective immunity to TB," Nature Reviews. Microbiology, vol. 12, no. 4, pp. 289-299, 2014.
34. M. V. da Silva, A. A. Figueiredo, J. R. Machado et al., "T cell activation and proinflammatory cytokine production in clinically cured tuberculosis are time-dependent and accompanied by upregulation of IL-10," PloS One, vol. 8, no. 6, article e65492, 2013.
35. J. L. Flynn, M. M. Goldstein, J. Chan et al., "Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice," Immunity, vol. 2, no. 6, pp. 561-572, 1995.
36. A. G. Bean, D. R. Roach, H. Briscoe et al., "Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin," Journal of Immunology, vol. 162, no. 6, pp. 3504-3511, 1999.
37. V. P. Mohan, C. A. Scanga, K. Yu et al., "Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology," Infection and Immunity, vol. 69, no. 3, pp. 1847-1855, 2001.
38. J. L. Flynn and J. Chan, "What's good for the host is good for the bug," Trends in Microbiology, vol. 13, no. 3, pp. 98-102, 2005.
39. J. Harris and J. Keane, "How tumour necrosis factor blockers interfere with tuberculosis immunity," Clinical and Experimental Immunology, vol. 161, no. 1, pp. 1-9, 2010.
40. P. Jayaraman, I. Sada-Ovalle, T. Nishimura et al., "IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation," Journal of Immunology, vol. 190, no. 8, pp. 4196-4204, 2013.
41. K. D. Mayer-Barber and A. Sher, "Cytokine and lipid mediator networks in tuberculosis," Immunological Reviews, vol. 264, no. 1, pp. 264-275, 2015.
42. C. Manca, L. Tsenova, S. Freeman et al., "Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway," Journal of Interferon & Cytokine Research, vol. 25, no. 11, pp. 694-701, 2005.
43. C. Manca, L. Tsenova, A. Bergtold et al., "Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5752-5757, 2001.
44. T. J. Scriba, B. Kalsdorf, D. A. Abrahams et al., "Distinct, specific IL-17-and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response," Journal of Immunology, vol. 180, no. 3, pp. 1962-1970, 2008.
45. R. Schindler, J. A. Gelfand, and C. A. Dinarello, "Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself," Blood, vol. 76, no. 8, pp. 1631-1638, 1990.
46. C. H. Ladel, C. Blum, A. Dreher, K. Reifenberg, M. Kopf, and S. H. Kaufmann, "Lethal tuberculosis in interleukin-6-deficient mutant mice," Infection and Immunity, vol. 65, no. 11, pp. 4843-4849, 1997.
47. P. A. Selwyn, D. Hartel, V. A. Lewis et al., "A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection," The New England Journal of Medicine, vol. 320, no. 9, pp. 545-550, 1989.
48. F. Cantini, E. Lubrano, A. Marchesoni et al., "Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey," International Journal of Rheumatic Diseases, vol. 19, no. 8, pp. 799-805, 2016.
49. I. Solovic, M. Sester, J. J. Gomez-Reino et al., "The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement," The European Respiratory Journal, vol. 36, no. 5, pp. 1185-1206, 2010.
50. D. Bumbacea, S. M. Arend, F. Eyuboglu et al., "The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement," The European Respiratory Journal, vol. 40, no. 4, pp. 990-1013, 2012.
51. A. D. Harries, A. M. Kumar, S. Satyanarayana et al., "Addressing diabetes mellitus as part of the strategy for ending TB," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 110, no. 3, pp. 173-179, 2016.
52. K. Ronacher, S. A. Joosten, R. van Crevel, H. M. Dockrell, G. Walzl, and T. H. Ottenhoff, "Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus," Immunological Reviews, vol. 264, no. 1, pp. 121-137, 2015.
53. D. Goletti, A. Sanduzzi, and G. Delogu, "Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches," The Journal of Rheumatology. Supplement, vol. 91, pp. 24-31, 2014.
54. G. G. Mahairas, P. J. Sabo, M. J. Hickey, D. C. Singh, and C. K. Stover, "Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis," Journal of Bacteriology, vol. 178, no. 5, pp. 1274-1282, 1996.
55. N. C. Gey van Pittius, S. L. Sampson, H. Lee, Y. Kim, P. D. van Helden, and R. M. Warren, "Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions," BMC Evolutionary Biology, vol. 6, no. 1, p. 95, 2006.
56. H. S. Whitworth, M. Scott, D. W. Connell, B. Donges, and A. Lalvani, "IGRAs - the gateway to T cell based TB diagnosis," Methods, vol. 61, no. 1, pp. 52-62, 2013.
57. P. Andersen, M. E. Munk, J. M. Pollock, and T. M. Doherty, "Specific immune-based diagnosis of tuberculosis," Lancet, vol. 356, no. 9235, pp. 1099-1104, 2000.
58. "QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA package insert," http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf.
59. T. Mori, M. Sakatani, F. Yamagishi et al., "Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens," American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 1, pp. 59-64, 2004.
60. A. Penn-Nicholson, E. Nemes, W. A. Hanekom, M. Hatherill, and T. J. Scriba, "Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons," Tuberculosis (Edinburgh, Scotland), vol. 95, no. 3, pp. 350-351, 2015.
61. E. Petruccioli, T. Chiacchio, I. Pepponi et al., "First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus," The Journal of Infection, vol. 73, no. 6, pp. 588-597, 2016.
62. E. Petruccioli, A. Navarra, L. Petrone et al., "Use of several immunological markers to model the probability of active tuberculosis," Diagnostic Microbiology and Infectious Disease, vol. 86, no. 2, pp. 169-171, 2016.
63. T. Chiacchio, E. Petruccioli, V. Vanini et al., "Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients," The Journal of Infection, vol. 69, no. 6, pp. 533-545, 2014.
64. C. L. Day, D. A. Abrahams, L. Lerumo et al., "Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load," Journal of Immunology, vol. 187, no. 5, pp. 2222-2232, 2011.
65. V. Rozot, A. Patrizia, S. Vigano et al., "Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis," Clinical Infectious Diseases, vol. 60, no. 3, pp. 432-437, 2015.
66. V. Rozot, S. Vigano, J. Mazza-Stalder et al., "Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease," European Journal of Immunology, vol. 43, no. 6, pp. 1568-1577, 2013.
67. M. Nikolova, R. Markova, R. Drenska et al., "Antigen-specific CD4-and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection," Diagnostic Microbiology and Infectious Disease, vol. 75, no. 3, pp. 277-281, 2013.
68. M. R. Nyendak, D. M. Lewinsohn, R. D. Shah et al., "ATS Core Curriculum 2014: part I. Adult pulmonary medicine," Annals of the American Thoracic Society, vol. 11, no. 7, pp. 1136-1144, 2014.
69. L. Barcellini, E. Borroni, J. Brown et al., "First independent evaluation of QuantiFERON-TB Plus performance," The European Respiratory Journal, vol. 47, no. 5, pp. 1587-1590, 2016.
70. L. Barcellini, E. Borroni, J. Brown et al., "First evaluation of QuantiFERON-TB Gold Plus performance in contact screening," The European Respiratory Journal, vol. 48, no. 5, pp. 1411-1419, 2016.
71. L. Yi, Y. Sasaki, H. Nagai et al., "Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan," Scientific Reports, vol. 6, p. 30617, 2016.
72. H. Hoffmann, K. Avsar, R. Göres, S. C. Mavi, and S. Hofmann-Thiel, "Equal sensitivity of the new generation QuantiFERON-TB Gold Plus in direct comparison with the previous test version QuantiFERON-TB Gold IT," Clinical Microbiology and Infection, vol. 22, no. 8, pp. 701-703, 2016.
73. H. Aggerbeck, R. Giemza, P. Joshi et al., "Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection," PloS One, vol. 8, no. 5, article e64215, 2013.
74. K. A. Millington, S. M. Fortune, J. Low et al., "Rv3615c is a highly immunodominant RD1 (region of difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5730-5735, 2011.
75. J. P. Zellweger, G. Sotgiu, M. Block et al., "Risk assessment of tuberculosis in contacts by IFN-gamma release assays. A Tuberculosis Network European Trials Group Study," American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 10, pp. 1176-1184, 2015.
76. M. X. Rangaka, K. A. Wilkinson, J. R. Glynn et al., "Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis," The Lancet Infectious Diseases, vol. 12, no. 1, pp. 45-55, 2012.
77. D. E. Zak, A. Penn-Nicholson, T. J. Scriba et al., "AbloodRNA signature for tuberculosis disease risk: a prospective cohort study," Lancet, vol. 387, no. 10035, pp. 2312-2322, 2016.
78. R. Sloot, M. F. van der Loeff, E. W. van Zwet et al., "Biomarkers can identify pulmonary tuberculosis in HIVinfected drug users months prior to clinical diagnosis," eBioMedicine, vol. 2, no. 2, pp. 172-179, 2014.
79. H. A. Fletcher, M. A. Snowden, B. Landry et al., "T-cell activation is an immune correlate of risk in BCG vaccinated infants," Nature Communications, vol. 7, p. 11290, 2016.
80. H. A. Fletcher and L. Schrager, "TB vaccine development and the end TB strategy: importance and current status," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 110, no. 4, pp. 212-218, 2016.
81. E. Petruccioli, L. Petrone, V. Vanini et al., "Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis," The Journal of Infection, vol. 71, no. 5, pp. 526-533, 2015.
82. D. Portevin, F. Moukambi, P. Clowes et al., "Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study," The Lancet Infectious Diseases, vol. 14, no. 10, pp. 931-938, 2014.
83. T. Prezzemolo, G. Guggino, M. P. La Manna, D. Di Liberto, F. Dieli, and N. Caccamo, "Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis," Frontiers in Immunology, vol. 5, p. 180, 2014.
84. G. Delogu, V. Vanini, G. Cuzzi et al., "Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection," Scandinavian Journal of Immunology, vol. 84, no. 6, pp. 344-352, 2016.
85. N. Nishimoto, K. Yoshizaki, N. Miyasaka et al., "Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo controlled trial," Arthritis and Rheumatism, vol. 50, no. 6, pp. 1761-1769, 2004.
86. R. N. Maini, P. C. Taylor, J. Szechinski et al., "Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate," Arthritis and Rheumatism, vol. 54, no. 9, pp. 2817-2829, 2006.
87. N. Nishimoto, J. Hashimoto, N. Miyasaka et al., "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab," Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1162-1167, 2007.
88. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth et al., "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial," Lancet, vol. 371, pp. 987-997, 2008.
89. P. Emery, E. Keystone, H. P. Tony et al., "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial," Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1516-1523, 2008.
90. M. C. Genovese, J. D. McKay, E. L. Nasonov et al., "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study," Arthritis and Rheumatism, vol. 58, no. 10, pp. 2968-2980, 2008.
91. N. Nishimoto, N. Miyasaka, K. Yamamoto et al., "Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy," Modern Rheumatology, vol. 19, no. 1, pp. 12-19, 2009.
92. N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and J. Azuma, "Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study," Annals of the Rheumatic Diseases, vol. 68, pp. 1580-1584, 2009.
93. G. Jones, A. Sebba, J. Gu et al., "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study," Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 88-96, 2010.
94. Y. Hirabayashi, T. Ishii, and H. Harigae, "Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice," Rheumatology International, vol. 30, no. 8, pp. 1041-1048, 2010.
95. H. Yamanaka, Y. Tanaka, E. Inoue et al., "Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)," Modern Rheumatology, vol. 21, no. 2, pp. 122-133, 2011.
96. G. R. Burmester, E. Feist, H. Kellner, J. Braun, C. Iking-Konert, and A. Rubbert-Roth, "Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)," Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 755-759, 2011.
97. J. M. Kremer, R. Blanco, M. Brzosko et al., "Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year," Arthritis and Rheumatism, vol. 63, no. 3, pp. 609-621, 2011.
98. T. Takeuchi, Y. Tanaka, K. Amano et al., "Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study," Rheumatology (Oxford), vol. 50, no. 10, pp. 1908-1915, 2011.
99. K. Kume, K. Amano, S. Yamada, K. Hatta, H. Ohta, and N. Kuwaba, "Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial," The Journal of Rheumatology, vol. 38, no. 10, pp. 2169-2171, 2011.
100. Y. Yazici, J. R. Curtis, A. Ince et al., "Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study," Annals of the Rheumatic Diseases, vol. 71, no. 2, pp. 198-205, 2012.
101. M. Dougados, K. Kissel, T. Sheeran et al., "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)," Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 43-50, 2013.
102. V. P. Bykerk, A. J. Ostör, J. Alvaro-Gracia et al., "Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice," Annals of the Rheumatic Diseases, vol. 71, no. 12, pp. 1950-1954, 2012.
103. V. Strand, G. R. Burmester, S. Ogale, J. Devenport, A. John, and P. Emery, "Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study," Rheumatology (Oxford), vol. 51, no. 10, pp. 1860-1869, 2012.
104. C. Gabay, P. Emery, R. van Vollenhoven et al., "Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial," The Lancet, vol. 381, no. 9877, pp. 1541-1550, 2013.
105. G. R. Burmester, A. Rubbert-Roth, A. Cantagrel et al., "A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)," Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 69-74, 2014.
106. A. Ogata, K. Tanimura, T. Sugimoto et al., "Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis," Arthritis Care & Research (Hoboken), vol. 66, no. 3, pp. 344-354, 2014.
107. J. M. Álvaro-Gracia, A. Fernández-Nebro, A. García-López et al., "Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice," Reumatología Clínica, vol. 10, no. 2, pp. 94-100, 2014.
108. M. Dougados, K. Kissel, P. G. Conaghan et al., "Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study," Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 803-809, 2014.
109. Y. Nakashima, M. Kondo, T. Fukuda et al., "Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data," Modern Rheumatology, vol. 24, no. 2, pp. 258-264, 2014.
110. A. Kivitz, E. Olech, M. Borofsky et al., "Subcutaneous tocilizumab versus placebo in combination with diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis," Arthritis Care & Research (Hoboken), vol. 66, no. 11, pp. 1653-1661, 2014.
111. V. P. Bykerk, A. J. Östör, J. Alvaro-Gracia et al., "Comparison of tocilizumab as monotherapy or with add-on diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice," Clinical Rheumatology, vol. 34, no. 3, pp. 563-571, 2015.
112. G. R. Burmester, A. Rubbert-Roth, A. Cantagrel et al., "Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)," Annals of the Rheumatic Diseases, vol. 75, no. 1, pp. 68-74, 2016.
113. J. M. Kremer, R. Blanco, A. M. Halland et al., "Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial," Clinical and Experimental Rheumatology, vol. 34, no. 4, pp. 625-633, 2016.
114. J. W. Bijlsma, P. M. Welsing, T. G. Woodworth et al., "Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial," Lancet, vol. 388, no. 10042, pp. 343-355, 2016.
115. R. Sakai, S. K. Cho, T. Nanki et al., "Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry," Arthritis Research & Therapy, vol. 17, p. 74, 2015.
116. T. Koike, M. Harigai, S. Inokuma et al., "Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients," Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2148-2151, 2011.
117. World Health Organization Global Tuberculosis Report 2012. WHO Library Cataloguing-in-Publication Data, Information Resource Centre HTM/STB World Health Organization, Geneve, Switzerland, ISBN 9789241564502, http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf.
118. M. H. Schiff, J. M. Kremer, A. Jahreis, E. Vernon, J. D. Isaacs, and R. F. van Vollenhoven, "Integrated safety in tocilizumab clinical trials," Arthritis Research & Therapy, vol. 13, no. 5, p. R141, 2011.
119. C. O. Bingham III, "Emerging therapeutics for rheumatoid arthritis," Bulletin of the NYU Hospital for Joint Diseases, vol. 66, no. 3, pp. 210-215, 2008.
120. J. C. Edwards, L. Szczepanski, J. Szechinski et al., "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis," The New England Journal of Medicine, vol. 350, no. 25, pp. 2572-2581, 2004.
121. P. J. Mease, D. A. Revicki, J. Szechinski et al., "Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial," The Journal of Rheumatology, vol. 35, no. 1, pp. 20-30, 2008.
122. P. J. Mease, S. Cohen, N. B. Gaylis et al., "Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial," The Journal of Rheumatology, vol. 37, no. 5, pp. 917-927, 2010.
123. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska et al., "The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial," Arthritis and Rheumatism, vol. 54, no. 5, pp. 1390-1400, 2006.
124. S. B. Cohen, P. Emery, M. W. Greenwald et al., "Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks," Arthritis and Rheumatism, vol. 54, no. 9, pp. 2793-2806, 2006.
125. A. Rubbert-Roth, P. P. Tak, C. Zerbini et al., "Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)," Rheumatology (Oxford), vol. 49, no. 9, pp. 1683-1693, 2010.
126. P. Emery, A. Deodhar, W. F. Rigby et al., "Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))," Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1629-1635, 2010.
127. M. W. Greenwald, W. J. Shergy, J. L. Kaine, M. T. Sweetser, K. Gilder, and M. D. Linnik, "Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial," Arthritis and Rheumatism, vol. 63, no. 3, pp. 622-632, 2011.
128. P. P. Tak, W. F. Rigby, A. Rubbert-Roth et al., "Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early activerheumatoid arthritis: the IMAGE trial," Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 39-46, 2011.
129. L. Brulhart, A. Ciurea, A. Finckh et al., "Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study," Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1255-1257, 2006.
130. R. N. Jois, A. Masding, M. Somerville, K. Gaffney, and D. G. Scott, "Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience," Rheumatology (Oxford), vol. 46, no. 6, pp. 980-982, 2007.
131. D. McGonagle, A. L. Tan, J. Madden, L. Taylor, and P. Emery, "Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARDresistantrheumatoid arthritis," Rheumatology (Oxford), vol. 47, no. 6, pp. 865-867, 2008.
132. R. M. Thurlings, K. Vos, D. M. Gerlag, and P. P. Tak, "Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders," Arthritis and Rheumatism, vol. 58, no. 12, pp. 3657-3664, 2008.
133. J. Sellam, H. Hendel-Chavez, S. Rouanet et al., "B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study," Arthritis and Rheumatism, vol. 63, no. 4, pp. 933-938, 2011.
134. B. Haraoui, M. Bokarewa, I. Kallmeyer, V. P. Bykerk, and R. E. S. E. T. Investigators, "Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial," The Journal of Rheumatology, vol. 38, no. 12, pp. 2548-2556, 2011.
135. J. J. Gomez-Reino, J. R. Maneiro, J. Ruiz et al., "Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR study," Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1861-1864, 2012.
136. A. Isvy, M. Meunier, C. Gobeaux-Chenevier et al., "Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections," Joint, Bone, Spine, vol. 79, no. 4, pp. 365-369, 2012.
137. J. Narvaez, C. Díaz-Torné, J. M. Ruiz et al., "Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs," Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 991-997, 2011.
138. R. F. van Vollenhoven, P. Emery, C. O. Bingham 3rd et al., "Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients," Annals of the Rheumatic Diseases, vol. 72, no. 9, pp. 1496-1502, 2013.
139. K. L. Winthrop, S. Yamashita, S. E. Beekmann, P. M. Polgreen, and Infectious Diseases Society of America Emerging Infections Network, "Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network," Clinical Infectious Diseases, vol. 46, no. 11, pp. 1738-1740, 2008.
140. T. L. Liao, C. H. Lin, Y. M. Chen, C. L. Chang, H. H. Chen, and D. Y. Chen, "Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan," PloS One, vol. 11, no. 4, article e0153217, 2016.
141. S. Ottaviani, J. Tiendrebeogo, L. Choudat et al., "Knee tuberculosis under rituximab therapy for rheumatoid arthritis," Joint, Bone, Spine, vol. 80, no. 4, pp. 435-436, 2012.
142. J. E. Gottenberg, P. Ravaud, T. Bardin et al., "Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry," Arthritis and Rheumatism, vol. 62, no. 9, pp. 2625-2632, 2010.
143. H. P. Tony, G. Burmester, H. Schulze-Koops et al., "Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)," Arthritis Research & Therapy, vol. 13, no. 13, p. R75, 2011.
144. D. Vassilopoulos, E. M. Delicha, L. Settas et al., "Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study," Clinical and Experimental Rheumatology, vol. 34, no. 5, pp. 893-900, 2016.
145. J. Wendler, G. R. Burmester, H. Sörensen et al., "Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, noninterventional study in 2,484 patients," Arthritis Research & Therapy, vol. 16, no. 2, p. R80, 2014.
146. Y. M. Chen, H. H. Chen, K. L. Lai, W. T. Hung, J. L. Lan, and D. Y. Chen, "The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection," Rheumatology (Oxford), vol. 52, no. 4, pp. 697-704, 2013.
147. Y. Pehlivan, B. Kisacik, V. K. Bosnak, and A. M. Onat, "Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis," BML Case Reports, vol. 2013, 2013.
148. P. Xanthouli, S. Sailer, and C. Fiehn, "Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center," The Open Rheumatology Journal, vol. 6, pp. 286-289, 2012.
149. M. H. Buch, J. S. Smolen, N. Betteridge et al., "Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 909-920, 2011.
150. L. W. Moreland, R. Alten, F. Van den Bosch et al., "Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion," Arthritis and Rheumatism, vol. 46, no. 6, pp. 1470-1479, 2002.
151. G. Bernal-Fernandez, P. Espinosa-Cueto, R. Leyva-Meza, N. Mancilla, and R. Mancilla, "Decreased expression of T-cell costimulatory molecule CD28 on CD4 and CD8 T cells of Mexican patients with pulmonary tuberculosis," Tuberculosis Research and Treatment, vol. 2010, Article ID 517547, 8 pages, 2010.
152. J. M. Kremer, R. Westhovens, M. Leon et al., "Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig," The New England Journal of Medicine, vol. 349, no. 20, pp. 1907-1915, 2003.
153. J. M. Kremer, M. Dougados, P. Emery et al., "Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, doubleblind, randomized, placebo-controlled trial," Arthritis and Rheumatism, vol. 52, no. 10, pp. 2263-2271, 2005.
154. M. C. Genovese, J. C. Becker, M. Schiff et al., "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition," The New England Journal of Medicine, vol. 353, no. 11, pp. 1114-1123, 2005.
155. R. Westhovens, J. C. Cole, T. Li et al., "Improved healthrelated quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial," Rheumatology (Oxford), vol. 45, no. 10, pp. 1238-1246, 2006.
156. P. Emery, M. Kosinski, T. Li et al., "Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life," The Journal of Rheumatology, vol. 33, no. 4, pp. 681-689, 2006.
157. J. M. Kremer, H. K. Genant, L. W. Moreland et al., "Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial," Annals of Internal Medicine, vol. 144, no. 12, pp. 865-876, 2006.
158. M. Weinblatt, M. Schiff, A. Goldman et al., "Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial," Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 228-234, 2007.
159. M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. C. Becker, and E. Keystone, "Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebocontrolled study," Arthritis and Rheumatism, vol. 54, no. 9, pp. 2807-2816, 2006.
160. M. Schiff, M. Keiserman, C. Codding et al., "Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate," Annals of the Rheumatic Diseases, vol. 67, no. 8, pp. 1096-1103, 2008.
161. M. Schiff, C. Pritchard, J. E. Huffstutter et al., "The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial," Annals of the Rheumatic Diseases, vol. 68, no. 11, pp. 1708-1714, 2009.
162. R. Westhovens, M. Robles, A. C. Ximenes et al., "Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors," Annals of the Rheumatic Diseases, vol. 68, no. 12, pp. 1870-1877, 2009.
163. P. Emery, P. Durez, M. Dougados et al., "Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)," Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 510-516, 2010.
164. M. C. Genovese, A. Covarrubias, G. Leon et al., "Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate," Arthritis and Rheumatism, vol. 63, no. 10, pp. 2854-2864, 2011.
165. E. C. Keystone, J. M. Kremer, A. Russell et al., "Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study," Annals of the Rheumatic Diseases, vol. 71, no. 6, pp. 857-861, 2012.
166. M. Schiff, M. E. Weinblatt, R. Valente et al., "Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial," Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 86-94, 2014.
167. P. Emery, G. R. Burmester, V. P. Bykerk et al., "Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period," Annals of the Rheumatic Diseases, vol. 74, no. 1, pp. 19-26, 2015.
168. J. M. Kremer, A. S. Russell, P. Emery et al., "Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial," Annals of the Rheumatic Diseases, vol. 70, no. 10, pp. 1826-1830, 2011.
169. J. M. Kremer, C. Peterfy, A. S. Russell et al., "Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial," The Journal of Rheumatology, vol. 41, no. 6, pp. 1077-1087, 2014.
170. R. Westhovens, J. M. Kremer, P. Emery et al., "Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study," Clinical and Experimental Rheumatology, vol. 32, no. 4, pp. 553-562, 2014.
171. X. Mariette, J. E. Gottenberg, P. Ravaud, and B. Combe, "Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries," Rheumatology (Oxford), vol. 50, pp. 222-229, 2011.
172. N. Takahashi, T. Kojima, A. Kaneko et al., "Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks," The Journal of Rheumatology, vol. 42, no. 5, pp. 786-793, 2015.
173. M. Montepaone, E. Lubrano, A. Carboni, and A. Spadaro, "Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis," Open Access Rheumatology: Research and Reviews, vol. 6, pp. 7-13, 2014.
174. J. Leipe, M. Grunke, C. Dechant et al., "Role of Th17 cells in human autoimmune arthritis," Arthritis and Rheumatism, vol. 62, no. 10, pp. 2876-2885, 2010.
175. A. Gottlieb, A. Menter, A. Mendelsohn et al., "Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial," Lancet, vol. 373, no. 9664, pp. 633-640, 2009.
176. I. B. McInnes, A. Kavanaugh, A. B. Gottlieb et al., "Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial," Lancet, vol. 382, no. 9894, pp. 780-789, 2013.
177. C. Ritchlin, P. Rahman, A. Kavanaugh et al., "Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial," Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 990-999, 2014.
178. A. Kavanaugh, L. Puig, A. B. Gottlieb et al., "Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial," Arthritis Care & Research (Hoboken), vol. 67, no. 12, pp. 1739-1749, 2015.
179. T. F. Tsai, V. Ho, M. Song et al., "The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection," The British Journal of Dermatology, vol. 167, no. 5, pp. 1145-1152, 2012.
180. R. E. Kalb, D. F. Fiorentino, M. G. Lebwohl et al., "Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)," JAMA Dermatology, vol. 151, no. 9, pp. 961-969, 2015.
181. I. B. McInnes, J. Sieper, J. Braun et al., "Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial," Annals of the Rheumatic Diseases, vol. 73, no. 2, pp. 349-356, 2014.
182. I. B. McInnes, P. J. Mease, B. Kirkham et al., "Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial," Lancet, vol. 386, no. 9999, pp. 1137-1146, 2015.
183. P. J. Mease, I. B. McInnes, B. Kirkham et al., "Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis," The New England Journal of Medicine, vol. 373, no. 14, pp. 1329-1339, 2015.
184. D. Baeten, X. Baraliakos, J. Braun et al., "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial," Lancet, vol. 382, no. 9906, pp. 1705-1713, 2013.
185. D. Baeten, J. Sieper, J. Braun et al., "Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis," The New England Journal of Medicine, vol. 373, no. 26, pp. 2534-2548, 2015.
186. A. Blauvelt, "Safety of secukinumab in the treatment of psoriasis," Expert Opinion on Drug Safety, vol. 15, no. 10, pp. 1413-1420, 2016.
187. F. Cantini and D. Goletti, "Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence," The Journal of Rheumatology. Supplement, vol. 91, pp. 1-3, 2014.
188. J. A. Singh, D. E. Furst, A. Bharat et al., "2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis," Arthritis Care & Research (Hoboken), vol. 64, no. 5, pp. 625-639, 2012.
189. J. S. Smolen, R. Landewé, F. C. Breedveld et al., "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update," Annals of the Rheumatic Diseases, vol. 73, no. 3, pp. 492-509, 2014.
190. F. Cantini, L. Niccoli, C. Nannini et al., "Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis," Seminars in Arthritis and Rheumatism, vol. 45, no. 5, pp. 519-532, 2016.
191. L. C. Coates, A. Kavanaugh, P. J. Mease et al., "Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis," Arthritis & Rhematology, vol. 68, no. 5, pp. 1060-1071, 2016.
192. M. M. Ward, A. Deodhar, E. A. Akl et al., "American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis," Arthritis & Rhematology, vol. 68, no. 2, pp. 282-298, 2016.
193. J. Braun, R. van den Berg, X. Baraliakos et al., "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis," Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 896-904, 2011.